<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/wp-content/plugins/xml-sitemap-feed/assets/sitemap-news.xsl?ver=5.7.7"?>
<!-- generated-on="2026-08-23T12:46:56+00:00" -->
<!-- generator="XML Sitemap & Google News for WordPress" -->
<!-- generator-url="https://status301.net/wordpress-plugins/xml-sitemap-feed/" -->
<!-- generator-version="5.7.7" -->
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" >
<url><loc>https://diabeticinsieme.it/eli-lilly-ritiro-insuline-mercato-europeo/</loc><news:news><news:publication><news:name>Diabetic Insieme</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-08-23T05:53:51+02:00</news:publication_date><news:title>Eli Lilly ritira diverse insuline dal mercato europeo entro il 2027</news:title></news:news></url>
<url><loc>https://diabeticinsieme.it/diabete-tipo-2-giovani-adulti-inghilterra-studio/</loc><news:news><news:publication><news:name>Diabetic Insieme</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-08-23T05:53:35+02:00</news:publication_date><news:title>Il diabete di tipo 2 cresce tra i giovani adulti in Inghilterra, piu marcato nelle donne</news:title></news:news></url>
<url><loc>https://diabeticinsieme.it/sensore-glicemico-impiantabile-sangue-glucotrack/</loc><news:news><news:publication><news:name>Diabetic Insieme</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-08-23T05:53:23+02:00</news:publication_date><news:title>Un sensore glicemico impiantabile nella vena punta a durare tre anni, Glucotrack verso il trial</news:title></news:news></url>
<url><loc>https://diabeticinsieme.it/perdere-peso-non-basta-diabete-studio-tulip/</loc><news:news><news:publication><news:name>Diabetic Insieme</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-08-23T05:53:10+02:00</news:publication_date><news:title>Perdere peso non basta a evitare il diabete in un sottogruppo ad alto rischio, lo studio Tulip</news:title></news:news></url>
</urlset>
